Test Details
Methodology
Immunoassay
Result Turnaround Time
Within 1 day
Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary.
Test Includes
Procainamide; N-acetyl procainamide (NAPA)
Custom Additional Information
The cardiac actions of this drug are similar to those of quinidine. It is used in a variety of arrhythmias. Procainamide usually is rapidly absorbed from the gastrointestinal tract. Peak blood levels are reached within one hour. Optimal plasma sampling time after oral dosage is one to two hours. Optimal sampling time after I.V. administration of dose is 30 minutes. The drug is converted by the liver to its active metabolite, N-acetyl procainamide (NAPA). The half-life of procainamide is two to six hours and for NAPA is eight hours. Rate of metabolism is genetically determined (slow and fast acetylator types) contributing to significant interindividual variability. Impairment of renal function has pronounced effect on drug disposition, especially for NAPA. Patients with severe renal dysfunction generally have prolonged and highly variable half-life characteristics. Elimination half-life may be prolonged in geriatric subjects.1
Specimen Requirements
Specimen
Serum or plasma
Volume
1 mL
Minimum Volume
0.3 mL
Container
Red-top tube or green-top (heparin) tube. Do not use a gel-barrier tube. The use of gel-barrier tubes is not recommended due to slow absorption of the drug by the gel. Depending on the specimen volume and storage time, the decrease in drug level due to absorption may be clinically significant.
Collection Instructions
Transfer separated serum or plasma to a plastic transport tube. Oral treatment: peak: 75 minutes after dose; trough: immediately before next dose. I.V. treatment: immediately after loading dose; 2, 6, 12, and 24 hours after starting I.V. maintenance.
Stability Requirements
Temperature | Period |
---|---|
Room temperature | 2 days |
Refrigerated | 14 days |
Frozen | 14 days |
Freeze/thaw cycles | Stable x3 |
Reference Range
Therapeutic: procainamide: 4.0−10.0 μg/mL, procainamide + NAPA: 10.0−30.0 μg/mL
Storage Instructions
Refrigerate
Causes for Rejection
Gel-barrier tube; severe hemolysis; lipemia; icteric specimen
Footnotes
LOINC® Map
Order Code | Order Code Name | Order Loinc | Result Code | Result Code Name | UofM | Result LOINC |
---|---|---|---|---|---|---|
007252 | Procainamide, Serum | 88699-4 | 018666 | Procainamide, Serum | ug/mL | 3982-6 |
007252 | Procainamide, Serum | 88699-4 | 018459 | NAPA, Serum | ug/mL | 3834-9 |
007252 | Procainamide, Serum | 88699-4 | 022287 | Total PA+NAPA | ug/mL | 3983-4 |
Order Code | 007252 | |||||
Order Code Name | Procainamide, Serum | |||||
Order Loinc | 88699-4 | |||||
Result Code | 018666 | |||||
Result Code Name | Procainamide, Serum | |||||
UofM | ug/mL | |||||
Result LOINC | 3982-6 | |||||
Order Code | 007252 | |||||
Order Code Name | Procainamide, Serum | |||||
Order Loinc | 88699-4 | |||||
Result Code | 018459 | |||||
Result Code Name | NAPA, Serum | |||||
UofM | ug/mL | |||||
Result LOINC | 3834-9 | |||||
Order Code | 007252 | |||||
Order Code Name | Procainamide, Serum | |||||
Order Loinc | 88699-4 | |||||
Result Code | 022287 | |||||
Result Code Name | Total PA+NAPA | |||||
UofM | ug/mL | |||||
Result LOINC | 3983-4 |